Randomized phase II trial evaluating trastuzumab + capecitabine (HX) or lapatinib + capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes.
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2017
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ELTOP
- 10 Jan 2017 Status changed from active, no longer recruiting to completed.
- 08 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 02 Jun 2012 Trial design presented at the 48th Annual Meeting of the American Society of Clinical Oncology.